Michael Massaro serves as Dalya Partners’ Executive Leader – Clinical.

Michael joined Rovia (formerly ECIR) as CEO in January 2024. As CEO, Michael was responsible for providing strategic leadership, driving business growth, and ensuring operational excellence within the organization.

Prior to this, Michael served as senior vice president and general partner for what was then PRA, a global contract research organization. Shortly after joining, Michael was appointed to the role of global head of biometrics.

In October 2019, he added responsibility for project delivery to his remit. In this role, he led global project delivery and biometrics, which included approximately 1,500 staff managing 450+ clinical projects with P/L responsibility across two distinct business units totaling approximately $350M in annual revenue (and $5.5B in total contract value) and growing in double-digit percentages year over year.

Most previously, Michael served as vice president, clinical operations, responsible for all clinical development activity at Vtesse, a clinical stage rare-disease start-up based in Gaithersburg, MD. In his role, Michael oversaw the launch and conduct of the clinical program of the company’s product candidate VTS-270, being investigated for treatment of patients with Niemann-Pick Type C-1 (NPC1).

Michael has been in clinical development for over 30 years, beginning his career at Abbott Laboratories.